PLatelet aggregation and Aspirin low response in Type One Diabetes and the association with vascular damage and diabetic Nephropathy
Key facts
- Where
- Herlev, DániaSee the site
- Phase
- 2. fázis
Where in Dánia
- Steno Diabetes Center CopenhagenHerlev, DániaToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Steno Diabetes Center Copenhagen
- Trial code
- EU 2024-520324-29-00
- Record updated
- 2025. január 22.
- Original description
Investigate platelet aggregation in T1D without/off aspirin treatment, stratified according to degree of albuminuria, compared to healthy controls. Platelet aggregation is determined by arachidonic acid expressed as area under the curve.Read full original descriptionShow less
Investigate platelet aggregation in T1D without/off aspirin treatment, stratified according to degree of albuminuria, compared to healthy controls. Platelet aggregation is determined by arachidonic acid expressed as area under the curve.
Inclusion: Type 1 diabetes. (Only for the type 1 diabetes population.); Male and female participants > 18 years of age; Capable of giving informed consent.
Exclusion: Intake of any antithrombotic medication or fish oil, or intake of NSAIDs within the past 14 days. (Only healthy controls.); Treatment with adenosine diphosphate ADP-receptor inhibitors, NSAID within the past 14 days, fish oil or other antithrombotic treatment, e.g. vitamin K antagonists and NOAKs. Only the type 1 diabetes population; Non-diabetic kidney disease. (Only the type 1 diabetes population.); Liver disease (liver cirrhosis with current impaired liver function defined as ALAT more than two times the upper limit at last control.) (Only the type 1 diabetes population.); High risk of thrombosis, i.e., Stroke, TIA or drug eluting stent within the last 6 months or acute coronary syndrome within the last 6 weeks or within 12 months from complications to acute coronary syndrome. (Only the type 1 diabetes population.); Known hypersensitivity or intolerance to aspirin. (Only the type 1 diabetes population.); Chronic systemic disease. (Only healthy controls.); Pregnancy or breastfeeding; Persons who, in the judgement of the investigator, are incapable of participating; Participation in another intervention study.